Aevi Genomic Medicine (GNMX) Stock Price, News & Analysis

Company Overview

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Key Stats

• Today's Range: $0.15 to $0.18
• 50-Day Range: $0.17 to $0.19
• 52-Week Range: $0.11 to $0.35
• Volume: 2.95 million shs
• Average Volume: 3.16 million shs
• Market Capitalization: $12.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNMX Stock Analysis - Frequently Asked Questions

How were Aevi Genomic Medicine's earnings last quarter?

Aevi Genomic Medicine, LLC (NASDAQ:GNMX) announced its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03.

What other stocks do shareholders of Aevi Genomic Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aevi Genomic Medicine investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX), Protalix BioTherapeutics (PLX), iBio (IBIO), Immunomedics (IMMU) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/01/2018
• Today: 6/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GNMX
• Previous Symbol: NASDAQ:MDGN
• CIK: 1138776
• Web: www.aevigenomics.com
• Phone: 610-254-4201
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -898.31%
• Return on Assets: -286.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.65
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 1.38

Miscellaneous

• Outstanding Shares: 77,714,000
• Free Float: N/A
• Market Cap: $12.89 million
• Optionable: Optionable
• Beta: 1.13